The FDA has classified as Class II an ongoing recall of carbamazepine tablets USP 200 mg in 1000-count bottles, manufactured by Taro Pharmaceutical Industries in Haifa Bay, Israel, with Sun Pharmaceutical Industries Inc named as the recalling firm. The reason given is deviation from current good manufacturing practice, with black spots on tablets arising from burnt excipient during manufacture. The classification was posted on 26 August 2026.
This is the second carbamazepine quality recall classified on the same date, from a different manufacturing route. Class II means exposure may cause temporary or medically reversible harm and serious injury is unlikely; it describes a visible defect in the tablet, not a problem with the drug. Nothing in the classification asserts sub-potency, and it is not a safety communication about carbamazepine's known risks.
The practical concern is the same as with any anti-seizure drug recall: what the patient does when a bottle is withdrawn. Two recalls of the same strength and formulation within one classification round raise the chance of a local supply gap, and an unplanned switch of manufacturer or a missed few days is the part that reaches the clinic as a seizure. The recall names a US recalling firm and US distribution; it makes no statement about carbamazepine supplied in India, and the CDSCO position on these lots is not addressed.
- Tell any patient who reports speckled or discoloured tablets to keep taking them until a replacement is in hand.
- Anticipate a supply pinch: two Class II recalls of 200 mg carbamazepine were classified on the same date.
- When the manufacturer changes, warn about breakthrough seizures and consider a level in a patient near the therapeutic margin.
- Class II is a product quality classification — do not relay it to patients as a new safety warning about the drug.
- The recall covers US distribution only; it says nothing about Indian supply.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free